Global Biopsy Guidance System Market to reach USD 1.31 billion by 2027.Global Biopsy guidance system Market is valued approximately at USD 0.92 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 5.20 % over the forecast period 2021-2027. Biopsy Guidance System is used for the diagnosis of cancer and other chronic diseases in their initial stage. The Biopsy Guidance System market is being driven by growing cases of cancer globally, increase in the geriatric population, an increasing preference for non-invasive procedures, technological advancements, and increasing government initiatives. For instance, according to Cancer.org, in 2021, the amount of new cancer patients will be around 1.9 million in U.S. As the biopsy guidance system is one of the major tools required for the initial diagnosis of cancer, thus, rising number of cancer cases is estimated to drive market growth over the forecast period. In addition, advancement in technologies such as robot-assisted biopsy, needle-based biopsy guns etc. may fuel the market growth. However, risk of infections associated with the use of biopsy needles may impede market growth over the forecast period of 2021-2027.

The regional analysis of the Biopsy Guidance System Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. Asia Pacific is a significant region across the world in terms of market share due to high prevalence of cancer in the region. Whereas North America is also anticipated to exhibit the highest CAGR over the forecast period 2021-2027, due to increasing cases of cancer and advancement in biopsy guidance systems in the region.
Major market player included in this report are:
C. R. Bard, Inc
Becton, Dickinson and Company
Hologic, Inc.
Devicor Medical Products, Inc.
B. Braun Melsungen AG
ARGON MEDICAL
Boston Scientific Corporation
INRAD Inc.
Cook Medical
PLANMED OY
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product Type:
Stereotactic Guided Biopsy
Ultrasound Guided Biopsy
MRI Guided Biopsy
By End-use:
Hospitals
Specialty Clinics
Diagnostic Centers
Research and Academic Institute
By Application:
Brain Biopsy
Breast Biopsy
Other Application

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027.

Target Audience of the Biopsy Guidance System (PSF) Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors